Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors
Abstract Background To evaluate the efficacy and safety of abiraterone acetate (AA) plus prednisone compared with prednisone alone in Asian patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC), and to identify predictive factors. Methods We reviewed the medical re...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-12-01
|
| Series: | BMC Urology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12894-018-0416-6 |
| _version_ | 1828857776524230656 |
|---|---|
| author | Liancheng Fan Baijun Dong Chenfei Chi Yanqing Wang Yiming Gong Jianjun Sha Jiahua Pan Xun Shangguan Yiran Huang Lixin Zhou Wei Xue |
| author_facet | Liancheng Fan Baijun Dong Chenfei Chi Yanqing Wang Yiming Gong Jianjun Sha Jiahua Pan Xun Shangguan Yiran Huang Lixin Zhou Wei Xue |
| author_sort | Liancheng Fan |
| collection | DOAJ |
| description | Abstract Background To evaluate the efficacy and safety of abiraterone acetate (AA) plus prednisone compared with prednisone alone in Asian patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC), and to identify predictive factors. Methods We reviewed the medical records of 60 patients with chemotherapy-naive mCRPC at Renji Hospital who were treated with AA plus prednisone (n = 43) or prednisone alone (n = 17). All patients were assessed for prostate-specific antigen (PSA) response, PSA progression-free survival (PSA PFS), radiographic progression-free survival (rPFS), and overall survival (OS). The ability of several parameters to predict PSA PFS, rPFS, and OS was studied. Results The median follow-up time was 14.0 months (range 7.0–18.5 months), at which time 19 death events had been reported: 11 in the AA + prednisone group and 8 in the prednisone group. The AA + prednisone group had significantly longer median PSA PFS (10.3 vs 3.0 months, P < 0.001), rPFS (13.9 vs 3.9 months, P < 0.001), and OS (23.3 vs 17.5 months, P = 0.016) than the prednisone-alone group. The most frequently reported grade 3 or 4 adverse event in both the AA + prednisone and prednisone-alone groups was elevated alanine aminotransferase level in 5 of 43 patients (11.6%) and 2 of 17 patients (11.8%), respectively. No adverse events led to discontinuation of therapy. In multivariate analysis, time from androgen deprivation therapy (ADT) to castration resistance of ≤18 months was a determinant of shorter OS (P = 0.007). Conclusions These results support the favourable safety and efficacy profile of AA for the treatment of Asian patients with chemotherapy-naive mCRPC. Longer duration of ADT response was significantly associated with longer survival. |
| first_indexed | 2024-12-13T01:43:39Z |
| format | Article |
| id | doaj.art-e7b6703134b645aa97978440ec9f4486 |
| institution | Directory Open Access Journal |
| issn | 1471-2490 |
| language | English |
| last_indexed | 2024-12-13T01:43:39Z |
| publishDate | 2018-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Urology |
| spelling | doaj.art-e7b6703134b645aa97978440ec9f44862022-12-22T00:03:42ZengBMCBMC Urology1471-24902018-12-011811810.1186/s12894-018-0416-6Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factorsLiancheng Fan0Baijun Dong1Chenfei Chi2Yanqing Wang3Yiming Gong4Jianjun Sha5Jiahua Pan6Xun Shangguan7Yiran Huang8Lixin Zhou9Wei Xue10Department of Urology, School of Medicine, Renji Hospital, Shanghai Jiao Tong UniversityDepartment of Urology, School of Medicine, Renji Hospital, Shanghai Jiao Tong UniversityDepartment of Urology, School of Medicine, Renji Hospital, Shanghai Jiao Tong UniversityDepartment of Urology, School of Medicine, Renji Hospital, Shanghai Jiao Tong UniversityDepartment of Urology, School of Medicine, Renji Hospital, Shanghai Jiao Tong UniversityDepartment of Urology, School of Medicine, Renji Hospital, Shanghai Jiao Tong UniversityDepartment of Urology, School of Medicine, Renji Hospital, Shanghai Jiao Tong UniversityDepartment of Urology, School of Medicine, Renji Hospital, Shanghai Jiao Tong UniversityDepartment of Urology, School of Medicine, Renji Hospital, Shanghai Jiao Tong UniversityDepartment of Urology, School of Medicine, Renji Hospital, Shanghai Jiao Tong UniversityDepartment of Urology, School of Medicine, Renji Hospital, Shanghai Jiao Tong UniversityAbstract Background To evaluate the efficacy and safety of abiraterone acetate (AA) plus prednisone compared with prednisone alone in Asian patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC), and to identify predictive factors. Methods We reviewed the medical records of 60 patients with chemotherapy-naive mCRPC at Renji Hospital who were treated with AA plus prednisone (n = 43) or prednisone alone (n = 17). All patients were assessed for prostate-specific antigen (PSA) response, PSA progression-free survival (PSA PFS), radiographic progression-free survival (rPFS), and overall survival (OS). The ability of several parameters to predict PSA PFS, rPFS, and OS was studied. Results The median follow-up time was 14.0 months (range 7.0–18.5 months), at which time 19 death events had been reported: 11 in the AA + prednisone group and 8 in the prednisone group. The AA + prednisone group had significantly longer median PSA PFS (10.3 vs 3.0 months, P < 0.001), rPFS (13.9 vs 3.9 months, P < 0.001), and OS (23.3 vs 17.5 months, P = 0.016) than the prednisone-alone group. The most frequently reported grade 3 or 4 adverse event in both the AA + prednisone and prednisone-alone groups was elevated alanine aminotransferase level in 5 of 43 patients (11.6%) and 2 of 17 patients (11.8%), respectively. No adverse events led to discontinuation of therapy. In multivariate analysis, time from androgen deprivation therapy (ADT) to castration resistance of ≤18 months was a determinant of shorter OS (P = 0.007). Conclusions These results support the favourable safety and efficacy profile of AA for the treatment of Asian patients with chemotherapy-naive mCRPC. Longer duration of ADT response was significantly associated with longer survival.http://link.springer.com/article/10.1186/s12894-018-0416-6AbirateroneMetastatic castration-resistant prostate cancerChemotherapy-naiveResponse to previous therapy |
| spellingShingle | Liancheng Fan Baijun Dong Chenfei Chi Yanqing Wang Yiming Gong Jianjun Sha Jiahua Pan Xun Shangguan Yiran Huang Lixin Zhou Wei Xue Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors BMC Urology Abiraterone Metastatic castration-resistant prostate cancer Chemotherapy-naive Response to previous therapy |
| title | Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors |
| title_full | Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors |
| title_fullStr | Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors |
| title_full_unstemmed | Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors |
| title_short | Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors |
| title_sort | abiraterone acetate for chemotherapy naive metastatic castration resistant prostate cancer a single centre prospective study of efficacy safety and prognostic factors |
| topic | Abiraterone Metastatic castration-resistant prostate cancer Chemotherapy-naive Response to previous therapy |
| url | http://link.springer.com/article/10.1186/s12894-018-0416-6 |
| work_keys_str_mv | AT lianchengfan abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors AT baijundong abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors AT chenfeichi abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors AT yanqingwang abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors AT yiminggong abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors AT jianjunsha abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors AT jiahuapan abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors AT xunshangguan abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors AT yiranhuang abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors AT lixinzhou abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors AT weixue abirateroneacetateforchemotherapynaivemetastaticcastrationresistantprostatecancerasinglecentreprospectivestudyofefficacysafetyandprognosticfactors |